Healthcare resource utilization and costs associated with incremental systemic corticosteroid exposure in asthma.

ABSTRACT:

Background

Although systemic corticosteroid (SCS) treatment, irrespective of duration or dosage, is associated with adverse outcomes for patients with asthma, the longitudinal effects of this treatment on adverse outcomes, healthcare resource utilization (HCRU), and healthcare costs are unknown.

Methods

We identified patients initiating intermittent or long-term SCS who were diagnosed with active asthma from UK general practice with linked secondary care data. Control (non-SCS) patients were matched by sex and index date with those initiating SCS. Minimum baseline period was 1 year prior to index date; minimum follow-up duration was 2 years post-index date. Cumulative incidence of SCS-associated adverse outcomes and associated HCRU and costs were compared between SCS and non

SUBMITTER: Voorham J 

PROVIDER: S-EPMC6587525 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature